Details of the Drug

General Information of Drug (ID: DMYS6MW)

Drug Name
GCS-100
Indication
Disease Entry ICD 11 Status REF
Chronic kidney disease GB61 Phase 2 [1]
Cross-matching ID
UNII
3HO3IZ2ILX
DrugBank ID
DB17566
TTD ID
D0JW0V

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Galectin (LGALS) TTX1OI0 NOUNIPROTAC Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01843790) A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease. U.S. National Institutes of Health.
2 GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010 May 13;115(19):3939-48.